SCHEMBL17093430

SCHEMBL17093430

CN(N=C(c1ccccc1)c1ccccc1)C(N)=NO

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CTSL P07711 2/20 0.51
▸ CTSK P43235 1/20 0.51
▸ ALDH1A1 P00352 3/20 0.50
▸ GFER P55789 2/20 0.50
▸ HPGD P15428 2/20 0.50
▸ CYP2C19 P33261 2/20 0.41
▸ GAA P10253 2/20 0.41
▸ KMT2A Q03164 2/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ CTSB P07858 1/20 0.37
▸ MAPT P10636 3/20 0.36
▸ POLB P06746 2/20 0.36
▸ XBP1 P17861 1/20 0.36
▸ BLM P54132 2/20 0.35
▸ F2 P00734 1/20 0.35
▸ F10 P00742 1/20 0.35
▸ F12 P00748 1/20 0.35
▸ F7 P08709 1/20 0.35
▸ F3 P13726 1/20 0.35
▸ PKM P14618 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15616898 1.00 CTSL (0.51) CTSLCTSKALDH1A1GFERHPGD
SCHEMBL10498731 0.74 ALDH1A1 (0.50) CTSLCTSKALDH1A1GFERHPGD
SCHEMBL17093429 0.70 CTSL (0.42) CTSLCTSKALDH1A1GFERHPGD
SCHEMBL11699938 0.69 ALDH1A1 (0.50) CTSLCTSKALDH1A1GFERHPGD
SCHEMBL11836951 0.69 SIGMAR1 (0.53) ALDH1A1GFERHPGDL3MBTL1LMNA
SCHEMBL11836941 0.69 SIGMAR1 (0.53) ALDH1A1GFERHPGDL3MBTL1LMNA
SCHEMBL273196 0.69 HPGD (0.64) ALDH1A1GFERHPGDCYP2C19GAA
SCHEMBL27961040 0.69 HPGD (0.64) ALDH1A1GFERHPGDCYP2C19GAA
SCHEMBL15549217 0.67 ALDH1A1 (0.47) CTSLCTSKALDH1A1GFERHPGD
SCHEMBL4379211 0.67 G6PC1 (0.50) CTSLCTSKALDH1A1GFERHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240276957-A1 METHODS OF TREATMENT WITH AMINOLEVULINIC ACID SYNTHASE 2 (ALAS2) MODULATORS AGIOS PHARMACEUTICALS, INC. 2024-08-22 — — US disclosed
CN-114174288-A Methods of treatment with aminolevulinic acid synthase 2(ALAS2) modulators 安吉奥斯医药品有限公司 2022-03-11 — — CN disclosed
WO-2020247819-A2 METHODS OF TREATMENT WITH AMINOLEVULINIC ACID SYNTHASE 2 (ALAS2) MODULATORS AGIOS PHARMACEUTICALS, INC. (US) 2020-12-10 — — WO disclosed
EP-2877457-B1 CYSTATHIONINE-GAMMA-LYASE (CSE) INHIBITORS SOVA PHARMACEUTICALS INC (US) 2020-09-23 — — EP disclosed
US-20170327478-A1 CYSTATHIONINE-GAMMA-LYASE (CSE) INHIBITORS SOVA PHARMACEUTICALS, INC. 2017-11-16 — — US disclosed
US-9725426-B2 Cystathionine-γ-lyase (CSE) inhibitors SOVA PHARMACEUTICALS, INC. (US) 2017-08-08 — — US disclosed
US-20150272934-A1 USE OF CSE INHIBITORS FOR THE TREATMENT OF CUTANEOUS INJURIES OR CONDITIONS AND SLEEP-RELATED BREATHING DISORDERS SOVA PHARMACEUTICALS, INC. 2015-10-01 — — US disclosed
US-20150266837-A1 CYSTATHIONINE-GAMMA-LYASE (CSE) INHIBITORS SOVA PHARMACEUTICALS, INC. 2015-09-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170327478-A1 CYSTATHIONINE-GAMMA-LYASE (CSE) INHIBITORS CBS, CTH, BHMT CTSL 1648/4885CTSK 1364/4885ALDH1A1 954/4885
US-20150266837-A1 CYSTATHIONINE-GAMMA-LYASE (CSE) INHIBITORS CBS, CTH, BHMT CTSL 1648/4885CTSK 1364/4885ALDH1A1 954/4885
US-20150272934-A1 USE OF CSE INHIBITORS FOR THE TREATMENT OF CUTANEOUS INJURIES OR CONDITIONS AND SLEEP-RELATED BREATHING DISORDERS HIF1AN, CBS, COXFA4L2 CTSL 1340/4885CTSK 612/4885ALDH1A1 974/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback